Alnylam Pharmaceuticals, Inc.
ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products includeā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$449.16
Price-1.06%
-$4.81
1Y
Price
Market Cap
$59.340b
Large
Price/Earnings 3y Avg5y Avg
1,403.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+23.8%
EBITDA Margin+20.1%
Net Profit Margin+25.1%
Free Cash Flow MarginRevenue
$3.210b
+42.8%
1y CAGR+47.3%
3y CAGR+41.2%
5y CAGREarnings
$43.565m
+115.7%
1y CAGR+71.2%
3y CAGR+45.2%
5y CAGREPS
$0.24
+111.0%
1y CAGR+70.4%
3y CAGR+45.5%
5y CAGRBook Value
$233.894m
$4.852b
Assets$4.618b
Liabilities$2.773b
DebtDebt to Assets
57.2%
14.9x
Debt to EBITDAFree Cash Flow
$221.364m
+619.8%
1y CAGR+175.0%
3y CAGR+134.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company